Janssen unveils data from first phase-3 trial of single-tablet regimen
Category: #health  By Pankaj Singh  Date: 2019-04-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Janssen unveils data from first phase-3 trial of single-tablet regimen

The outcomes from the first prospective Phase 3 trial studying the rapid initiation of a single-tablet regimen were published at the 13th ACTHIV 2019 conference

Janssen Pharmaceutical Companies of Johnson & Johnson has reportedly released new 48-week data for SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg D/C/F/TAF). As per trusted sources, the data demonstrates that a high proportion of HIV patients attained an undetectable viral load through 48 weeks following the rapid start of SYMTUZA®.

According to a press release by Janssen, a secondary endpoint of the study also revealed that 97 percent of patients stated they were gratified with the treatment. The outcomes from the first prospective Phase 3 trial studying the rapid initiation of a single-tablet regimen – DIAMOND study – were published at the 13th Annual American Conference for the Treatment of HIV (ACTHIV 2019) in Miami, Florida.

Infectious Disease Director of Midway Immunology and Research Center at Fort Pierce, Florida, Moti Ramgopal, M.D., was reportedly quoted saying that the rapid initiation of antiretroviral treatment is becoming the recognized standard of care for newly diagnosed HIV-1 patients since it can enhance treatment outcomes.

It includes the probability of an individual adhering to treatment and staying in care. Moreover, it can be an additional strategy in the firm’s goal to achieve the 90/90/90 prevention and treatment goals as outlined by UNAIDS, Ramgopal further added.

Reportedly, the DIAMOND study assessed the once-daily STR SYMTUZA® to treat HIV type 1 (HIV-1) infection in adult patients who had signed up within 14 days of obtaining an HIV diagnosis. All these patients then commenced the intake of SYMTUZA® before laboratory or baseline resistance test outcomes were made available.

The U.S. Food & Drug Administration (FDA) has approved SYMTUZA® for the treatment of HIV-1 infection in certain virologically suppressed and treatment-naïve adults.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Experian takes over MyHealthDirect for patient engagement and access
Experian takes over MyHealthDirect for patient engagement and access
By Pankaj Singh

  • MyHealthDirect’s easy-to-understand technology guides its patients to profound and right care.
  • Acquisition of MyHealthDirect would strengthen...

Amazon rolls out Scout autonomous delivery robots in California
Amazon rolls out Scout autonomous delivery robots in California
By Pankaj Singh

  • The company brings out its 6-wheeled, sidewalk-driving delivering robot for delivery in the Irvine area of California.
     
  • The driverless...

hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
By Pankaj Singh

This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects.

hVIVO plc has re...